Keyphrases
Pharmacokinetics
46%
Acute Myeloid Leukemia
36%
Phase I Study
33%
Docetaxel
33%
Sorafenib
31%
Pharmacokinetic Study
29%
Paclitaxel
24%
Human Plasma
22%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
21%
OATP1B1
16%
Cytarabine
15%
Tyrosine Kinase Inhibitor
15%
Dose Level
14%
Topotecan
13%
Cancer Patients
12%
FMS-like Tyrosine Kinase 3 (FLT3)
12%
Cytochrome P450 3A (CYP3A)
12%
Metabolism
12%
Clinical Pharmacology
12%
Cytochrome P450 3A4 (CYP3A4)
11%
Nucleoside Analogues
11%
Relapsed or Refractory Acute Myeloid Leukemia
11%
Glucuronide
10%
Solid Tumors
10%
Advanced Solid Malignancies
10%
Pharmacologic
10%
Gefitinib
10%
Drug Interactions
10%
Neutropenia
10%
Refractory Solid Tumors
9%
Troxacitabine
9%
Dose-limiting Toxicity
9%
Phase I Trial
9%
Systemic Exposure
9%
In Cancer
9%
Sunitinib
8%
Toxicity Profile
8%
Continuous Infusion
8%
Mouse Plasma
8%
Irinotecan
8%
Imatinib
8%
Multikinase Inhibitor
7%
Pharmacodynamics
7%
Tumor Malignancy
7%
High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS)
7%
Pharmacokinetic Profile
7%
Benzoylurea
7%
Gilteritinib
7%
Dose Escalation
7%
Cisplatin
7%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
100%
Acute Myeloid Leukemia
38%
Docetaxel
34%
Sorafenib
30%
Paclitaxel
27%
Solid Malignant Neoplasm
26%
Malignant Neoplasm
22%
Cytarabine
17%
Pharmacodynamics
16%
Protein Tyrosine Kinase Inhibitor
16%
Neoplasm
15%
Topotecan
14%
CYP3A4
13%
Disease
12%
CYP3A
11%
Acetonitrile
11%
Nucleoside Analog
11%
Glucuronide
10%
Neutropenia
10%
Elimination
10%
Troxacitabine
10%
Leukemia
10%
Phase I Trials
9%
Sunitinib
8%
Irinotecan
8%
Gefitinib
8%
Anticarcinogen
8%
Clinical Pharmacology
8%
Temozolomide
8%
Chemotherapy
7%
Cisplatin
7%
Taxane
7%
High Performance Liquid Chromatography
7%
Gilteritinib
7%
Doxorubicin
7%
Phosphotransferase
7%
Maximum Tolerated Dose
6%
Biological Marker
6%
Imatinib
6%
Bioavailability
6%
Advanced Cancer
6%
Acute Leukemia
6%
Docosahexaenoic Acid
5%
Pemetrexed
5%
Cytochrome P450
5%
Electrospray Ionization
5%
Formate
5%
Arylbutyric Acid Derivative
5%
Decitabine
5%
Azacitidine
5%